New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy

CONTACT: CONTACT: For further information, please contact : Åsa Hillsten, Head of IR & Sustainability, Calliditas Tel.: +46 76 403 35 43, Email:asa.hillsten@calliditas.com The information was sent for publication, through the agency of the contact persons set out above, onOctober 27, 2023at09:15 a.m. CET. The following files are available for download: View original content:...

CONTACT:

For further information, please contact:

Åsa Hillsten, Head of IR & Sustainability, Calliditas

Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com

The information was sent for publication, through the agency of the contact persons set out above, on October 27, 2023 at 09:15 a.m. CET.

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/new-drug-application-approval-by-the-pharmaceutical-administration-bureau-of-macau-for-nefecon-for-the-treatment-of-primary-iga-nephropathy-301969929.html